mCSPC incidence is increasing, as evidenced by US-based studies showing the shift in the stage of prostate cancer diagnosis, which is likely influenced by changes in prostate-specific antigen (PSA) screening recommendations by the US Preventative Services Task Force [5]. Here, KLK3 is linked to prostate carcinoma.